Obesity care's next generation will combine GLP-1 drugs with personalized therapies and advanced procedures
The article discusses how GLP-1 drugs like Ozempic, Wegovy, and Zepbound have transformed obesity treatment, but experts predict the future will go beyond these medications. The next generation of obesity care will combine drug therapies with personalized treatments, advanced procedures, and a more holistic approach to address the complex nature of obesity as a chronic disease.
Key quotes
Experts say the future of obesity treatment will extend far beyond GLP-1 drugs by combining medications with personalized therapies and advanced procedures.
The arrival of GLP-1 medications such as semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Mounjaro, Zepbound) has dramatically changed how obesity is treated.
But while these drugs have produced impressive results, experts say they are only one
From the article
You might also wanna read
Experts warn easy access to GLP-1 drugs may increase eating disorder risks
Experts are raising concerns that the widespread availability of GLP-1 drugs (like Ozempic and Wegovy) through telemedicine and oral formula
mdsc.pe·19d ago
GLP-1 Prescriptions Surge Sevenfold Among Women With PCOS: What to Know About Off-Label Use
GLP-1 drug prescriptions (like Ozempic, Wegovy, Zepbound, Mounjaro) among women with PCOS have surged over sevenfold since 2021, despite the
pcosnutrition.com·2d ago
Two Observational Studies Link GLP-1 Receptor Agonists to Reduced Breast Cancer Risk in Women with Obesity
Two observational studies found that GLP-1 receptor agonists (like Ozempic, Wegovy) are associated with reduced breast cancer incidence in w
mdsc.pe·13d ago
Study: Ozempic and Wegovy Reduce Household Food Spending and Change Purchasing Patterns
New research published in the Journal of Marketing Research shows that GLP-1 receptor agonist drugs like Ozempic and Wegovy are significantl
news.cornell.edu·5mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance, experts warn
This article discusses the risks of conflicts of interest in clinical guidance for GLP-1 receptor agonists (like Ozempic, Wegovy) used for o
bit.ly·19d ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
Comments
Sign in to join the conversation.
No comments yet. Be the first.